A voluntary recall of superpotent thyroid tablets has been reclassified as Class I, the FDA's most serious category, affecting nearly 2,000 bottles distributed nationwide.
U.S. health regulators have raised the stakes on a thyroid medication recall, upgrading it to the Food and Drug Administration's highest-risk classification. The move comes after testing showed certain thyroid tablets could be stronger than labeled, posing potential health risks to patients who rely on precise hormone dosing.
Recall upgraded to Class I
On September 22, the FDA reclassified a voluntary recall of Thyroid Tablets, USP made by Vitruvias Therapeutics Inc. as a Class I recall—the agency's most serious category. A Class I designation means there is a reasonable probability that using or being exposed to the product could cause serious adverse health consequences or death, according to the FDA's definition.usatoday+2
The recall originally began in late August after the manufacturer found that one lot of its 30 mg (½ Grain) thyroid tablets could be "superpotent," containing more active ingredient than stated on the label.usatoday+1
Which products are affected?
The recall involves a single lot of 30 mg thyroid tablets sold in 100-count bottles. Key identifiers include:usatoday+1
Product name: Thyroid Tablets, USP (30 mg / ½ Grain)
Lot number: 504950
National Drug Code (NDC): 69680-166-00
Expiration date: September 30, 2026
Distribution window: January 31 to September 30, 2025
Quantity: Approximately 1,955 bottles distributed nationwide (out of a batch of about 3,600 units)usatoday+1
The tablets contain two thyroid hormones—levothyroxine (T4) and liothyronine (T3)—in fixed amounts per tablet. When a product is superpotent, patients may receive more hormone than prescribed, which can disrupt thyroid balance and strain the cardiovascular system.news4jax
Why the recall matters for patients
Taking more thyroid hormone than intended can lead to symptoms of an overactive thyroid, including unintended weight loss, heat intolerance, fatigue, and elevated blood pressure. People with heart conditions or those particularly sensitive to thyroid hormones face higher risk of complications.usatoday+1
As of the August recall notice, Vitruvias Therapeutics reported no adverse events linked to the affected lot. However, the FDA's upgrade to Class I underscores the potential severity if superpotent tablets are consumed over time or by vulnerable patients.usatoday+1
What patients and pharmacies should do
The FDA and the company advise patients currently using the recalled tablets not to stop treatment abruptly. Instead, they should contact their healthcare provider for guidance on switching to an alternative supply or adjusting therapy safely.usatoday+1
Wholesalers and direct accounts were instructed to halt distribution and arrange for destruction of the recalled lot. Notifications were sent by letter to consignees and the public.news4jax+1
Consumers with questions can reach Vitruvias Therapeutics at safety@vitruvias.com or 256-239-9373.usatoday
Company status and distribution changes
Vitruvias Therapeutics has indicated online that it has ceased operations. According to one report, its products are now owned and/or distributed by H2-Pharma LLC, though the recall remains tied to the original Vitruvias lot.newsnationnow
What happens next
With the recall now classified at the highest risk level, regulators and healthcare providers are likely to increase outreach to ensure affected bottles are removed from circulation and patients are transitioned to safe alternatives. Patients are encouraged to check their medication bottles against the lot and NDC numbers above and consult their prescriber before making any changes.news4jax+1
KEY FACTS:
● The FDA has reclassified the recall of Vitruvias Therapeutics' 30 mg thyroid tablets as Class I, its most serious risk level.usatoday+1
● About 1,955 bottles (lot 504950, NDC 69680-166-00) distributed nationwide from Jan–Sept 2025 are affected; expiration date is Sept 30, 2026.usatoday+1
● Patients should not stop thyroid medication abruptly; they should contact their healthcare provider for guidance and check lot numbers.usatoday+1
SOURCES:
● USA TODAY — "Thyroid medicine recall receives FDA's highest risk level" https://www.usatoday.com/story/money/consumer-protection/recalls-alerts/2026/09/24/thyroid-tablet-medicine-recall-fda/91916444007/
● NewsNation — "FDA elevates thyroid tablet recall to most serious level" https://www.newsnationnow.com/health/fda-thyroid-tablet-recall-class-i/
● News4JAX — "Thyroid medication recall elevated to highest risk level by FDA" https://www.news4jax.com/news/local/2026/09/24/thyroid-medication-recall-elevated-to-highest-level-by-fda/
0 Comments